HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph User Fee Goals Document Beats Authorization To Finish Line

This article was originally published in The Pink Sheet

Executive Summary

While still awaiting the addition of OTC user fees to pending user fee authorization, and congressional approval of the overall package, FDA has developed guidelines closely tracking Sens. Isakson and Casey's OTC proposal. FDA plans a webinar to update industry on how OTC user fees would work.

You may also be interested in...



OTC Monograph Reform Emerges In Senate Proposal For Covid-19 Economic Relief

Senate pandemic economic relief legislation legislation would reform monograph drug program and allow purchases of OTC drugs with pre-tax health savings accounts. But lingering disagreements between Democrats and Republicans blocked the Senate's passage of the bill on 25 March.

FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill

Commissioner Gottlieb says agency won't issue layoff notices 'unless and until Sept. 30 passes without reauthorization.'

OTC Monograph User Fees Totaling $22m To $34m Floated In Senate Discussion Draft

Bulk of user fees would be raised through facility fees, under Sens. Isakson and Casey’s discussion draft, but there's little time to add the changes to FDA user fee reauthorization bills already moving in Congress.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel